Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer
Antibody drug conjugates (ADCs) are novel drugs that exert specific cytotoxicity against breast cancer. Although ADCs such as trastuzumab emtansine and trastuzumab deruxtecan have significantly improved survival for patients with breast cancer expressing HER2, there is still controversy over options...
Saved in:
Main Authors: | Hanghang Ma, Jianbin Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024176219 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer
by: Riqing Huang, et al.
Published: (2025-01-01) -
Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan
by: Ünal Metin Tokat, et al.
Published: (2025-01-01) -
The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
by: Anna-Maria Lazaratos, et al.
Published: (2024-12-01) -
Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus
by: Emad Dawoud, et al.
Published: (2025-01-01) -
Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs
by: Xiang Zhang, et al.
Published: (2025-02-01)